Abstract: Substantially anhydrous topical gel compositions comprising ingenol-3-angelate as a suspension in non-aqueous carriers.

Abstract: A sprayable film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a pharmaceutically acceptable propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethylether, and a mixture of dimethyl ether, diethylether and methylethyl ether, and a second propellant selected from C3-5 alkanes, hydrofluoroalkanes, hydrochloroalkanes, fluoroalkanes and chlorofluoroalkanes, the propellant being present in an amount of 50-99.5% w/w of the composition, the composition further comprising a film-forming polymer, a plasticizer and an oily release-enhancing agent.

Abstract: Novel aqueous topical gel compositions comprising ingenol-3-angelate.

Abstract: A topical pharmaceutical composition which is an oil-in-water-oil emulsion comprising a vitamin D derivative or analogue dissolved in a mixture of a non-ionic surfactant and a lower alkanol. The topical pharmaceutical composition may be used in the treatment of dermal conditions, such as psoriasis.

Abstract: Substantially anhydrous topical gel compositions comprising ingenol-3-angelate as a suspension in non-aqueous carriers.

Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.

Abstract: Novel aqueous topical gel compositions comprising ingenol-3-angelate.

Abstract: Topical gel composition comprising ingenol-3-angelate and a silicone.

Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.

Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative and a corticosteroid, and its use in the treatment of dermal diseases and conditions. The spray comprises especially a propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether or a mixture thereof and further a pharmaceutically acceptable lipid carrier solubilised or suspended in said propellant.

Abstract: A film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a volatile solvent, the composition further comprising a film-forming polymer, a plasticizer and an oily release-enhancing agent. The composition is capable of forming, after application on skin and evaporation of the solvent, a continuous phase comprising the film-forming polymer and the plasticizer and a dispersed phase comprising droplets of the oily release-enhancing agent.

Abstract: A sprayable film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a pharmaceutically acceptable propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethylether, and a mixture of dimethyl ether, diethylether and methylethyl ether, and a second propellant selected from C3-5 alkanes, hydrofluoroalkanes, hydrochloroalkanes, fluoroalkanes and chlorofluoroalkanes, the propellant being present in an amount of 50-99.5% w/w of the composition, the composition further comprising a film-forming polymer, a plasticizer and an oily release-enhancing agent.

Abstract: A substantially anhydrous pharmaceutical gel composition for cutaneous application comprising an ingenol derivative in dissolved or solubilized form, a solvent mixture of (a) a hydrophilic non-ionic surfactant; (b) a lipophilic non-ionic co-surfactant; (c) an oil; the composition further comprising an acidic compound, a co-solvent, a viscosity-increasing agent and a pharmaceutically acceptable, substantially anhydrous, non-solvent lipid carrier.

Abstract: A substantially anhydrous topical composition comprises a homogenous mixture of (a) a therapeutically effective amount of an ingenol derivative in dissolved form; (b) an oily solvent for the ingenol derivative, (c) an acidic compound, and (d) optionally a pharmaceutically acceptable non-solvent lipid carrier.

Abstract: Substantially anhydrous topical gel compositions comprising a homogeneous mixture of: (a) ingenol-3-angelate in dissolved form; and (b) anon-aqueous carrier.

Abstract: The present invention relates to a topical gel composition comprising ingenol-3-angelate, wherein the composition provides greater flux, according to the in vitro diffusion test, of ingenol-3-angelate into the stratum corneum, epidermis and dermis after application of the gel composition to skin than does a reference gel of ingenol-3-angelate, namely the PICATO® product.

Abstract: A topical composition for cutaneous application which is a water-in-oil emulsion comprises an oily phase comprising (a) an ingenol derivative in dissolved form; (b) at least one non-ionic surfactant selected from the group consisting of polyoxyl glycerides, polyoxyethylene castor oil derivatives, polyoxyethylene alkyl ethers, polysorbates, or a mixture of acrylamide acryloyldimethyl taurate copolymer, isohexadecane and polysorbate 80, sterols, fatty alcohols, fatty acid phosphonates, mono- or diglycol esters, mono- di- or polyglyceryl esters, mono-, di- or plyglucose esters, sucrose esters or sorbitan esters, the non-ionic surfactant being present in an amount of from about 0.5% by weight to about 10% by weight of the composition; (c) a solvent for the ingenol derivative; and an aqueous phase buffered to a pH of 2.6-3.7.

Abstract: Topical gel compositions comprising ingenol-3-angelate, wherein less than 10% of the ingenol-3-angelate degrades when the gel is stored for 2 years at 25° C.

Abstract: Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions.

Abstract: A pharmaceutical composition comprises, as a therapeutically active ingredient, a corticosteroid and/or vitamin D derivative incorporated as a solid solution or dispersion in lipid nanoparticles, said lipid nanoparticles being solid at ambient temperature and comprising a first lipid with a melting point above body temperature, the first lipid being a wax selected from the group consisting of esters of C12-24 alcohols and C12-24 fatty acids, glyceryl mono-, di- or triesters of C12-24 fatty acids, C12-24 fatty alcohols, and cholesterol, optionally a second lipid which is an oil at ambient temperature and miscible with the first lipid, and a pharmaceutically acceptable surfactant.